ABL1 and neoplasm: Genetic deletion of FOS inhibited tumor growth in a BCR‐ABL fusion protein kinase‐induced CML mouse model, and therefore, inhibition of high FOS expression reduced the intrinsic resistance of CML to TKI therapy (Kesarwani et al., 2017).